CF
RCUS icon

Centaurus Financial’s Arcus Biosciences RCUS Stock Holding History

Centaurus Financial’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,000
Closed -$24K – 1685
2018
Q2 		$24K Buy
+2,000
New +$31.4K ﹤0.01% 1198

Other funds holding RCUS

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Centaurus Financial's RCUS Position: Q3 2018 in Review

Centaurus Financial sold out of Arcus Biosciences (RCUS) in Q3 2018, closing a stake of 2,000 shares — an estimated $24K sold.

Centaurus Financial first reported a position in RCUS in Q2 2018 and held it in 1 quarter. The position peaked at $24K in Q2 2018. 57 funds tracked by Wall St. Rank hold RCUS as of Q3 2018.

  • Centaurus Financial reported no remaining Arcus Biosciences position as of Q3 2018 after selling out during the quarter.
  • Centaurus Financial sold 2,000 Arcus Biosciences shares in Q3 2018, an estimated $24K.
  • Centaurus Financial first reported a position in Arcus Biosciences in Q2 2018 and held it in 1 quarter.
  • Centaurus Financial's Arcus Biosciences position peaked at $24K in Q2 2018.
  • 57 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.